Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Auxiliary medicine for cancer and preparation thereof

A drug and cancer technology, applied in the field of preparation of the drug, can solve problems such as affecting treatment, losing opportunities for surgery, and difficult for patients to accept

Inactive Publication Date: 2003-09-03
成都利尔药业有限公司
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Primary liver cancer, bronchial lung cancer, and esophageal cancer are all common malignant tumors. When they are diagnosed, they are already in the middle and advanced stages, and the opportunity for surgery is lost. Many side effects caused by radiotherapy make it difficult for patients to accept and affect treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0013] The medicine and preparation method of the present invention will be further described through experiments below. These experiments include pharmacodynamic experiments, clinical experiments, and toxicological experiments. Experimental example 1 Effect of the medicine of the present invention on the transformation of mouse spleen lymphocytes and the production of IL-2

[0014] 1. Drugs and experimental materials

[0015] (1) The medicine of the present invention is made into capsules: specification: 0.25g / grain, every grain contains crude drug 1.55g, and medicine is mixed with 0.22g, 0.11g, 0.056g crude drug / ml suspension with 0.5% CMC-Na solution, Each group was intragastrically administered 0.5ml / 20g body weight according to body weight.

[0016] (2) ConA (product of Serva, Germany); RPMI1640 (product of GIBCO, USA); HurIL-2 standard product (product of Sigma, USA); H-Tdr (product of Beijing Institute of Atomic Energy, Chinese Academy of Sciences).

[0017] (3) Cycl...

experiment example 2

[0045] Confirm by above experimental result: medicine of the present invention can promote mouse splenic lymphocyte proliferation and promote the Th cell secretion IL-2 in splenocytes, each dosage group has significant difference (P<0.01) compared with blank control group; It can obviously resist the inhibitory effect of cyclophosphamide on the transformation of lymphocytes in experimental mice and the production of IL-2 by Th cells, and there is a significant difference (P<0.01) between the group of each dosage of the drug of the present invention plus cyclophosphamide and the group of cyclophosphamide. Experimental example 2 anti-hepatocarcinoma ascites type experiment of the medicine of the present invention

[0046] 1. Drugs and experimental materials

[0047] (1) The medicine of the present invention is made into capsules: specification: 0.25g / grain, every grain contains crude drug 1.55g, and medicine is mixed with 0.22g, 0.11g, 0.056g crude drug / ml suspension with 0.5% C...

experiment example 3

[0065] As can be seen from Table 3, the medicine of the present invention has the effect of prolonging the survival time to inoculated liver cancer ascites type mice, and there is significant difference (P<0.01) between high, middle and low dose groups and the blank control group, and the prolongation rate is respectively 40.7 %, 28.3%, 15.9%, three doses of the medicine of the present invention plus cyclophosphamide group mouse average survival days have significant difference (P<0.01) compared with cyclophosphamide group, and the prolongation rate obviously improves, shows that the medicine of the present invention has the effect on Cyclophosphamide has a synergistic effect against cancer. Experimental example 3 Anti-Ehrlich ascites cancer experiment of the present invention

[0066] 1. Drugs and experimental materials

[0067] (1) The medicine of the present invention is made into capsules: specification: 0.25g / grain, every grain contains crude drug 1.55g, and medicine is ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A Chinese medicine for helping the treatment of cancers, such as primary liver cancer, lung cancer and esophagus cancer, is prepared from 13 Chinese-medicinal materials including barbat skullcap, patrinia herb, zedoary, astragalus root, etc. Its advantage is high curative effect.

Description

technical field [0001] The invention relates to an auxiliary medicine for treating cancer. Specifically, the Chinese patent medicine is prepared from traditional Chinese medicine, and the invention also relates to a preparation method of the medicine. Background technique [0002] Primary liver cancer, bronchial lung cancer, and esophageal cancer are all common malignant tumors. When they are diagnosed, they are already in the middle and advanced stages, and the opportunity for surgery is lost. Many side effects caused by radiotherapy make it difficult for patients to accept and affect treatment. Traditional Chinese medicine believes that poison accumulation, blood stasis, and deficiency are the main etiology and pathology of tumors. From the perspective of modern medicine, low immune function of the body determines the onset and prognosis of tumors. Hypercoagulable state is conducive to cancer metastasis. Therefore, it is necessary to explore...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/48A61K35/62A61P35/00
Inventor 陈云华李军刘艳
Owner 成都利尔药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com